Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 222

1.

Survey of chiropractic clinicians on self-reported knowledge and recognition of concussion injuries.

Taylor DN, Wynd S.

Chiropr Man Therap. 2018 Jun 14;26:19. doi: 10.1186/s12998-018-0186-y. eCollection 2018. Review.

2.

Clinical endpoints in the controlled human challenge model for Shigella: A call for standardization and the development of a disease severity score.

Porter CK, Lynen A, Riddle MS, Talaat K, Sack D, Gutiérrez RL, McKenzie R, DeNearing B, Feijoo B, Kaminski RW, Taylor DN, Kirkpatrick BD, Bourgeois AL.

PLoS One. 2018 Mar 28;13(3):e0194325. doi: 10.1371/journal.pone.0194325. eCollection 2018.

3.

A Literature Review of Electronic Health Records in Chiropractic Practice: Common Challenges and Solutions.

Taylor DN.

J Chiropr Humanit. 2017 Jan 18;24(1):31-40. doi: 10.1016/j.echu.2016.12.001. eCollection 2017 Dec. Review.

4.

Medications for the prevention and treatment of travellers' diarrhea.

Taylor DN, Hamer DH, Shlim DR.

J Travel Med. 2017 Apr 1;24(suppl_1):S17-S22. doi: 10.1093/jtm/taw097. Review.

PMID:
28520998
5.

Survey of Primary Contact Medical and Chiropractic Clinicians on Self-Reported Knowledge and Recognition of Mild Traumatic Brain Injuries: A Pilot Study.

Taylor DN, Ponce FJ, Dyess SJ.

J Chiropr Med. 2017 Mar;16(1):19-30. doi: 10.1016/j.jcm.2016.10.005. Epub 2016 Dec 8.

6.

Randomized safety and immunogenicity trial of a seasonal trivalent inactivated split virion influenza vaccine (IVACFLU-S) in healthy young Vietnamese adults.

Anh DD, Thiem VD, Anh NTH, Huong VM, Nga NT, Thang TC, Thai DH, Chien VC, Holt R, Wahid R, Flores J, Berlanda Scorza F, Taylor DN.

Vaccine. 2016 Oct 26;34(45):5457-5462. doi: 10.1016/j.vaccine.2016.08.052. Epub 2016 Aug 24.

7.

An outbreak of Campylobacter enteritis associated with a community water supply on a U.S. military installation.

DeFraites RF, Sanchez JL, Brandt CA, Kadlec RP, Haberberger RL, Lin JJ, Taylor DN.

MSMR. 2014 Nov;21(11):10-5.

PMID:
25436877
8.

Development of VAX128, a recombinant hemagglutinin (HA) influenza-flagellin fusion vaccine with improved safety and immune response.

Taylor DN, Treanor JJ, Sheldon EA, Johnson C, Umlauf S, Song L, Kavita U, Liu G, Tussey L, Ozer K, Hofstaetter T, Shaw A.

Vaccine. 2012 Aug 24;30(39):5761-9. doi: 10.1016/j.vaccine.2012.06.086. Epub 2012 Jul 11.

PMID:
22796139
9.

A theoretical basis for maintenance spinal manipulative therapy for the chiropractic profession.

Taylor DN.

J Chiropr Humanit. 2011 Dec;18(1):74-85. doi: 10.1016/j.echu.2011.07.001. Epub 2011 Dec 6.

10.

Comparative evaluation of the antibody in lymphocyte supernatant (ALS) and enzyme-linked immunospot (ELISPOT) assays for measuring mucosal immune responses to Shigella antigens.

Feller AJ, McKenzie R, Taylor DN, Woods CC, Grahek SL, Islam D, Venkatesan MM, Hale TL, Bourgeois AL.

Vaccine. 2011 Nov 3;29(47):8487-9. doi: 10.1016/j.vaccine.2011.09.030. Epub 2011 Sep 20.

11.

Safety and immunogenicity of a recombinant M2e-flagellin influenza vaccine (STF2.4xM2e) in healthy adults.

Turley CB, Rupp RE, Johnson C, Taylor DN, Wolfson J, Tussey L, Kavita U, Stanberry L, Shaw A.

Vaccine. 2011 Jul 18;29(32):5145-52. doi: 10.1016/j.vaccine.2011.05.041. Epub 2011 May 30.

PMID:
21624416
12.

Induction of a potent immune response in the elderly using the TLR-5 agonist, flagellin, with a recombinant hemagglutinin influenza-flagellin fusion vaccine (VAX125, STF2.HA1 SI).

Taylor DN, Treanor JJ, Strout C, Johnson C, Fitzgerald T, Kavita U, Ozer K, Tussey L, Shaw A.

Vaccine. 2011 Jul 12;29(31):4897-902. doi: 10.1016/j.vaccine.2011.05.001. Epub 2011 May 17.

PMID:
21596084
13.

Immunopotentiation of trivalent influenza vaccine when given with VAX102, a recombinant influenza M2e vaccine fused to the TLR5 ligand flagellin.

Talbot HK, Rock MT, Johnson C, Tussey L, Kavita U, Shanker A, Shaw AR, Taylor DN.

PLoS One. 2010 Dec 28;5(12):e14442. doi: 10.1371/journal.pone.0014442.

14.

Safety and immunogenicity of a recombinant hemagglutinin influenza-flagellin fusion vaccine (VAX125) in healthy young adults.

Treanor JJ, Taylor DN, Tussey L, Hay C, Nolan C, Fitzgerald T, Liu G, Kavita U, Song L, Dark I, Shaw A.

Vaccine. 2010 Dec 6;28(52):8268-74. doi: 10.1016/j.vaccine.2010.10.009. Epub 2010 Oct 20.

PMID:
20969925
15.

Noroviruses as a cause of diarrhea in travelers to Guatemala, India, and Mexico.

Koo HL, Ajami NJ, Jiang ZD, Neill FH, Atmar RL, Ericsson CD, Okhuysen PC, Taylor DN, Bourgeois AL, Steffen R, DuPont HL.

J Clin Microbiol. 2010 May;48(5):1673-6. doi: 10.1128/JCM.02072-09. Epub 2010 Mar 19.

16.

Enterotoxigenic Escherichia coli and diffusely adherent E. coli as likely causes of a proportion of pathogen-negative travelers' diarrhea--a PCR-based study.

Meraz IM, Jiang ZD, Ericsson CD, Bourgeois AL, Steffen R, Taylor DN, Hernandez N, DuPont HL.

J Travel Med. 2008 Nov-Dec;15(6):412-8. doi: 10.1111/j.1708-8305.2008.00249.x.

17.

Safety and immunogenicity of WRSd1, a live attenuated Shigella dysenteriae type 1 vaccine candidate.

McKenzie R, Venkatesan MM, Wolf MK, Islam D, Grahek S, Jones AM, Bloom A, Taylor DN, Hale TL, Bourgeois AL.

Vaccine. 2008 Jun 19;26(26):3291-6. doi: 10.1016/j.vaccine.2008.03.079. Epub 2008 Apr 16.

PMID:
18468742
18.

Serum IgG antibody response to the protective antigen (PA) of Bacillus anthracis induced by anthrax vaccine adsorbed (AVA) among U.S. military personnel.

Singer DE, Schneerson R, Bautista CT, Rubertone MV, Robbins JB, Taylor DN.

Vaccine. 2008 Feb 13;26(7):869-73. doi: 10.1016/j.vaccine.2007.11.085. Epub 2007 Dec 26.

19.

Systemic pharmacokinetics of rifaximin in volunteers with shigellosis.

Taylor DN, McKenzie R, Durbin A, Carpenter C, Haake R, Bourgeois AL.

Antimicrob Agents Chemother. 2008 Mar;52(3):1179-81. Epub 2007 Dec 17.

20.

Response to letter to the editor "Zink TK. Vaccine 2007;25(15):2766-7".

Gorse GJ, Keitel W, Keyserling H, Taylor DN, Lock M, Alves K, Kenner J, Deans L, Gurwith M.

Vaccine. 2007 Oct 16;25(42):7285-7. Epub 2007 Aug 27. No abstract available.

PMID:
17850932
21.

Treatment of travelers' diarrhea: randomized trial comparing rifaximin, rifaximin plus loperamide, and loperamide alone.

Dupont HL, Jiang ZD, Belkind-Gerson J, Okhuysen PC, Ericsson CD, Ke S, Huang DB, Dupont MW, Adachi JA, De La Cabada FJ, Taylor DN, Jaini S, Martinez Sandoval F.

Clin Gastroenterol Hepatol. 2007 Apr;5(4):451-6. Epub 2007 Mar 26.

PMID:
17382603
22.

Spinal synovial cysts and intersegmental instability: a chiropractic case.

Taylor DN.

J Manipulative Physiol Ther. 2007 Feb;30(2):152-7.

PMID:
17320738
23.

Rifaximin treatment of pathogen-negative travelers' diarrhea.

DuPont HL, Haake R, Taylor DN, Ericsson CD, Jiang ZD, Okhuysen PC, Steffen R.

J Travel Med. 2007 Jan-Feb;14(1):16-9.

24.

Immune response, ciprofloxacin activity, and gender differences after human experimental challenge by two strains of enterotoxigenic Escherichia coli.

Coster TS, Wolf MK, Hall ER, Cassels FJ, Taylor DN, Liu CT, Trespalacios FC, DeLorimier A, Angleberger DR, McQueen CE.

Infect Immun. 2007 Jan;75(1):252-9. Epub 2006 Oct 30.

25.

Immunogenicity and tolerance of ascending doses of a recombinant protective antigen (rPA102) anthrax vaccine: a randomized, double-blinded, controlled, multicenter trial.

Gorse GJ, Keitel W, Keyserling H, Taylor DN, Lock M, Alves K, Kenner J, Deans L, Gurwith M.

Vaccine. 2006 Aug 14;24(33-34):5950-9. Epub 2006 Jun 5.

PMID:
16797805
26.

A randomized, double-blind, multicenter study of rifaximin compared with placebo and with ciprofloxacin in the treatment of travelers' diarrhea.

Taylor DN, Bourgeois AL, Ericsson CD, Steffen R, Jiang ZD, Halpern J, Haake R, Dupont HL.

Am J Trop Med Hyg. 2006 Jun;74(6):1060-6.

PMID:
16760520
27.

Rifaximin, a nonabsorbed oral antibiotic, prevents shigellosis after experimental challenge.

Taylor DN, McKenzie R, Durbin A, Carpenter C, Atzinger CB, Haake R, Bourgeois AL.

Clin Infect Dis. 2006 May 1;42(9):1283-8. Epub 2006 Mar 22.

PMID:
16586388
28.

Helicobacter pylori-associated chronic atrophic gastritis involving the gastric body and severe disease by Vibrio cholerae.

León-Barúa R, Recavarren-Arce S, Chinga-Alayo E, Rodríguez-Ulloa C, Taylor DN, Gotuzzo E, Kosek M, Eza D, Gilman RH.

Trans R Soc Trop Med Hyg. 2006 Jun;100(6):567-72. Epub 2005 Dec 22.

29.

Poorly absorbed antibiotics for the treatment of traveler's diarrhea.

Taylor DN.

Clin Infect Dis. 2005 Dec 1;41 Suppl 8:S564-70. Review.

PMID:
16267720
30.

Evaluation of Salmonella enterica serovar Typhi (Ty2 aroC-ssaV-) M01ZH09, with a defined mutation in the Salmonella pathogenicity island 2, as a live, oral typhoid vaccine in human volunteers.

Kirkpatrick BD, McKenzie R, O'Neill JP, Larsson CJ, Bourgeois AL, Shimko J, Bentley M, Makin J, Chatfield S, Hindle Z, Fidler C, Robinson BE, Ventrone CH, Bansal N, Carpenter CM, Kutzko D, Hamlet S, LaPointe C, Taylor DN.

Vaccine. 2006 Jan 12;24(2):116-23. Epub 2005 Aug 18.

PMID:
16140433
31.

Human caliciviruses as a cause of severe gastroenteritis in Peruvian children.

Parashar UD, Li JF, Cama R, DeZalia M, Monroe SS, Taylor DN, Figueroa D, Gilman RH, Glass RI.

J Infect Dis. 2004 Sep 15;190(6):1088-92. Epub 2004 Aug 2.

PMID:
15319858
32.

Occurrence and distribution of Vibrio cholerae in the coastal environment of Peru.

Gil AI, Louis VR, Rivera IN, Lipp E, Huq A, Lanata CF, Taylor DN, Russek-Cohen E, Choopun N, Sack RB, Colwell RR.

Environ Microbiol. 2004 Jul;6(7):699-706.

PMID:
15186348
33.

Two studies evaluating the safety and immunogenicity of a live, attenuated Shigella flexneri 2a vaccine (SC602) and excretion of vaccine organisms in North American volunteers.

Katz DE, Coster TS, Wolf MK, Trespalacios FC, Cohen D, Robins G, Hartman AB, Venkatesan MM, Taylor DN, Hale TL.

Infect Immun. 2004 Feb;72(2):923-30.

34.

Helicobacter pylori reinfection is common in Peruvian adults after antibiotic eradication therapy.

Soto G, Bautista CT, Roth DE, Gilman RH, Velapatiño B, Ogura M, Dailide G, Razuri M, Meza R, Katz U, Monath TP, Berg DE, Taylor DN; Gastrointestinal Physiology Working Group in Peru.

J Infect Dis. 2003 Nov 1;188(9):1263-75. Epub 2003 Oct 17.

PMID:
14593583
35.

Campylobacter transmission in a Peruvian shantytown: a longitudinal study using strain typing of campylobacter isolates from chickens and humans in household clusters.

Oberhelman RA, Gilman RH, Sheen P, Cordova J, Taylor DN, Zimic M, Meza R, Perez J, LeBron C, Cabrera L, Rodgers FG, Woodward DL, Price LJ.

J Infect Dis. 2003 Jan 15;187(2):260-9. Epub 2003 Jan 6.

PMID:
12552450
36.

Oral immunization of adult volunteers with microencapsulated enterotoxigenic Escherichia coli (ETEC) CS6 antigen.

Katz DE, DeLorimier AJ, Wolf MK, Hall ER, Cassels FJ, van Hamont JE, Newcomer RL, Davachi MA, Taylor DN, McQueen CE.

Vaccine. 2003 Jan 17;21(5-6):341-6.

PMID:
12531630
37.

Growth slowing after acute Helicobacter pylori infection is age-dependent.

Passaro DJ, Taylor DN, Gilman RH, Cabrera L, Parsonnet J.

J Pediatr Gastroenterol Nutr. 2002 Oct;35(4):522-6.

PMID:
12394378
38.

Phase I evaluation of delta virG Shigella sonnei live, attenuated, oral vaccine strain WRSS1 in healthy adults.

Kotloff KL, Taylor DN, Sztein MB, Wasserman SS, Losonsky GA, Nataro JP, Venkatesan M, Hartman A, Picking WD, Katz DE, Campbell JD, Levine MM, Hale TL.

Infect Immun. 2002 Apr;70(4):2016-21.

39.

Randomized, controlled human challenge study of the safety, immunogenicity, and protective efficacy of a single dose of Peru-15, a live attenuated oral cholera vaccine.

Cohen MB, Giannella RA, Bean J, Taylor DN, Parker S, Hoeper A, Wowk S, Hawkins J, Kochi SK, Schiff G, Killeen KP.

Infect Immun. 2002 Apr;70(4):1965-70.

40.

Safety and immunogenicity of a prototype enterotoxigenic Escherichia coli vaccine administered transcutaneously.

Güereña-Burgueño F, Hall ER, Taylor DN, Cassels FJ, Scott DA, Wolf MK, Roberts ZJ, Nesterova GV, Alving CR, Glenn GM.

Infect Immun. 2002 Apr;70(4):1874-80.

41.

Effects of nutritional status on diarrhea in Peruvian children.

Checkley W, Gilman RH, Black RE, Lescano AG, Cabrera L, Taylor DN, Moulton LH.

J Pediatr. 2002 Feb;140(2):210-8.

PMID:
11865273
42.

Acute Helicobacter pylori infection is followed by an increase in diarrheal disease among Peruvian children.

Passaro DJ, Taylor DN, Meza R, Cabrera L, Gilman RH, Parsonnet J.

Pediatrics. 2001 Nov;108(5):E87.

PMID:
11694671
43.

Parasitic infections of the gastrointestinal tract.

Katz DE, Taylor DN.

Gastroenterol Clin North Am. 2001 Sep;30(3):797-815, x. Review.

PMID:
11586558
44.

Posttreatment follow-up of Helicobacter pylori infection using a stool antigen immunoassay.

Roth DE, Taylor DN, Gilman RH, Meza R, Katz U, Bautista C, Cabrera L, Velapatiño B, Lebron C, Razúri M, Watanabe J, Monath T; Gastrointestinal Physiology Working Group.

Clin Diagn Lab Immunol. 2001 Jul;8(4):718-23.

45.

Safety and immunogenicity of a proteosome-Shigella flexneri 2a lipopolysaccharide vaccine administered intranasally to healthy adults.

Fries LF, Montemarano AD, Mallett CP, Taylor DN, Hale TL, Lowell GH.

Infect Immun. 2001 Jul;69(7):4545-53.

46.

Transcutaneous immunization: a human vaccine delivery strategy using a patch.

Glenn GM, Taylor DN, Li X, Frankel S, Montemarano A, Alving CR.

Nat Med. 2000 Dec;6(12):1403-6.

PMID:
11100128
47.
48.

Safety and immunogenicity of two different lots of the oral, killed enterotoxigenic escherichia coli-cholera toxin B subunit vaccine in Israeli young adults.

Cohen D, Orr N, Haim M, Ashkenazi S, Robin G, Green MS, Ephros M, Sela T, Slepon R, Ashkenazi I, Taylor DN, Svennerholm AM, Eldad A, Shemer J.

Infect Immun. 2000 Aug;68(8):4492-7.

49.

Two-year study of the protective efficacy of the oral whole cell plus recombinant B subunit cholera vaccine in Peru.

Taylor DN, Cárdenas V, Sanchez JL, Bégué RE, Gilman R, Bautista C, Perez J, Puga R, Gaillour A, Meza R, Echeverria P, Sadoff J.

J Infect Dis. 2000 May;181(5):1667-73. Epub 2000 May 15.

PMID:
10823767

Supplemental Content

Loading ...
Support Center